Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data

Jonathan Rabinowitz, Stephen Z. Levine, George Garibaldi, Dragana Bugarski-Kirola, Carmen Galani Berardo, Shitij Kapur

Research output: Contribution to journalArticlepeer-review

Abstract

Increased attention has been given to treatment of negative symptoms and its potential impact on functional outcomes, however previous inferences have been confounded by the fact that measures of functional outcomes often use items similar to those of negative symptoms. We attempted to discern the relative effects of negative symptoms on functioning, as compared to other symptoms, using data from the National Institute of Mental Health CATIE trial of chronic schizophrenia (n. =. 1447) by examining correlations of Positive and Negative Syndrome Scale factors, Calgary Depression Rating Scale and select items from Heinrich's and Lehman's Quality of Life Scales measuring aspects of functioning that did not overlap with negative symptoms. Baseline functioning and change in functioning were more strongly related to PANSS negative factor than any of the other symptoms - though the amount of variance explained by symptom changes in general was small. The data suggests that improvement in negative symptoms may have a distinctive and independent effect on functional outcome relative to other symptoms. This should be further tested in studies where negative symptoms improve without concomitant improvement of other symptoms.

Original languageEnglish
Pages (from-to)147-150
Number of pages4
JournalSchizophrenia Research
Volume137
Issue number1-3
DOIs
StatePublished - May 2012

Bibliographical note

Funding Information:
Drs. Garibaldi, Bugarski-Kirola and Galani Berardo are employees of F. Hoffmann-La Roche. Dr. Rabinowitz has received research support, and/or consultancy fees and/or travel support from Janssen (J&J), Eli Lilly, Pfizer, BiolineRx, F. Hoffmann-La Roche, Amgen and Newron Pharmaceuticals. Dr. Levine has received research support, and/or consultancy fees and/or travel support from F. Hoffmann-La Roche and Eli Lilly. Dr. Kapur has received grant support from GSK and has served as consultant and/or speaker for AstraZeneca, BiolineRx, BMS-Otsuka, Eli Lilly, Janssen (J&J), Lundbeck, NeuroSearch, Pfizer, F. Hoffmann-La Roche, Servier and Solvay Wyeth.

Funding Information:
Data used in the preparation of this article were obtained from the limited access datasets (version 1.7) distributed from the NIH-supported “ Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia ” (CATIE-Sz). This is a multisite clinical trial of persons with schizophrenia comparing the effectiveness of randomly assigned medication treatment. The study was supported by NIMH contract # N01MH90001 to the University of North Carolina at Chapel Hill. The ClinicalTrials.gov identifier is NCT00014001 . This presentation reflects the views of the authors and may not reflect the opinions or views of the CATIE-Sz Study Investigators or the NIH.

Keywords

  • Negative
  • Outcomes
  • Positive
  • Schizophrenia
  • Symptoms

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint

Dive into the research topics of 'Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data'. Together they form a unique fingerprint.

Cite this